Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

References

• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• WeinbergRAThe Biology of Cancer2nd edNew YorkGarland Science2014
   Google Scholar
• NairBCVadlamudiRKRegulation of hormonal therapy resistance by cell cycle machineryGene Ther Mol Biol20081239520148177
   PubMed Web of Science ®Google Scholar
• RobertsPJBisiJEStrumJCMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyJ Natl Cancer Inst2012104647648722302033
   PubMed Web of Science ®Google Scholar
• WeinbergRAThe retinoblastoma protein and cell cycle controlCell19958133233307736585
   PubMed Web of Science ®Google Scholar
• SchwartzGKShahMATargeting the cell cycle: a new approach to cancer therapyJ Clin Oncol200523369408942116361640
   PubMed Web of Science ®Google Scholar
• FryDWHarveyPJKellerPRSpecific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMol Cancer Ther20043111427143815542782
   PubMed Web of Science ®Google Scholar
• BoscoEEKnudsenESRB in breast cancer: at the crossroads of tumorigenesis and treatmentCell Cycle20076666767117361100
   PubMed Web of Science ®Google Scholar
• TrereDBrighentiEDonatiGHigh prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapyAnn Oncol200920111818182319556322
   PubMed Web of Science ®Google Scholar
• ArimaYInoueYShibataTRb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transitionCancer Res200868135104511218593909
   PubMed Web of Science ®Google Scholar
• MusgroveEASutherlandRLRB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative diseaseCell Cycle2010923460721260944
   PubMed Web of Science ®Google Scholar
• BoscoEEWangYXuHThe retinoblastoma tumor suppressor modifies the therapeutic response of breast cancerJ Clin Invest2007117121822817160137
   PubMed Web of Science ®Google Scholar
• MillarEKDeanJLMcNeilCMCyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcomeOncogene200928151812182019287456
   PubMed Web of Science ®Google Scholar
• ArnoldAPapanikolaouACyclin D1 in breast cancer pathogenesisJ Clin Oncol200523184215422415961768
   PubMed Web of Science ®Google Scholar
• LodenMStighallMNielsenNHThe cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb nodeOncogene200221304680469012096344
   PubMed Web of Science ®Google Scholar
• DeanJLThangavelCMcClendonAKReedCAKnudsenESTherapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failureOncogene201029284018403220473330
   PubMed Web of Science ®Google Scholar
• LeeJJKoEChoJMethylation and immunoexpression of p16(INK4a) tumor suppressor gene in primary breast cancer tissue and their quantitative p16(INK4a) hypermethylation in plasma by real-time PCRKorean J Pathol201246655456123323106
   PubMedGoogle Scholar
• DavalosARCoppeJPCampisiJDesprezPYSenescent cells as a source of inflammatory factors for tumor progressionCancer Metastasis Rev201029227328320390322
   PubMed Web of Science ®Google Scholar
• CoppeJPDesprezPYKrtolicaACampisiJThe senescence-associated secretory phenotype: the dark side of tumor suppressionAnnu Rev Pathol201059911820078217
   PubMed Web of Science ®Google Scholar
• LabergeRMAwadPCampisiJDesprezPYEpithelial-mesenchymal transition induced by senescent fibroblastsCancer Microenviron201251394421706180
   PubMedGoogle Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• ThangavelCDeanJLErtelATherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancerEndocr Relat Cancer201118333334521367843
   PubMed Web of Science ®Google Scholar
• WitkiewiczAKRivadeneiraDBErtelAAssociation of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironmentAm J Pathol201117931171117821756866
   PubMed Web of Science ®Google Scholar
• NadjiMGomez-FernandezCGanjei-AzarPMoralesARImmunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancersAm J Clin Pathol20051231212715762276
   PubMed Web of Science ®Google Scholar
• GnantMOvercoming endocrine resistance in breast cancer: importance of mTOR inhibitionExpert Rev Anticancer Ther201212121579158923253223
   PubMed Web of Science ®Google Scholar
• LehnSFernoMJirstromKRydenLLandbergGA non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifenCell Cycle201110695696221358261
   PubMed Web of Science ®Google Scholar
• ZwijsenRMWientjensEKlompmakerRvan der SmanJBernardsRMichalidesRJCDK-independent activation of estrogen receptor by cyclin D1Cell19978834054159039267
   PubMed Web of Science ®Google Scholar
• StendahlMKronbladARydenLEmdinSBengtssonNOLandbergGCyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patientsBr J Cancer200490101942194815138475
   PubMed Web of Science ®Google Scholar
• HuiRFinneyGLCarrollJSLeeCSMusgroveEASutherlandRLConstitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cellsCancer Res200262236916692312460907
   PubMed Web of Science ®Google Scholar
• WangYDeanJLMillarEKCyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonistsCancer Res200868145628563818632615
   PubMed Web of Science ®Google Scholar
• MillerTWBalkoJMFoxEMERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerCancer Discov20111433835122049316
   PubMed Web of Science ®Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• FinnRSDeringJConklinDPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res2009115R7719874578
   PubMed Web of Science ®Google Scholar
• DalvaiMBystrickyKCell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expressionPloS One201056e1101120543978
   PubMed Web of Science ®Google Scholar
• JohnsonSMTorriceCDBellJFMitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibitionJ Clin Invest201012072528253620577054
   PubMed Web of Science ®Google Scholar
• RobinsonTJLiuJCVizeacoumarFRB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugsPloS One2013811e7864124265703
   PubMed Web of Science ®Google Scholar
• McClendonAKDeanJLRivadeneiraDBCDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapyCell Cycle201211142747275522751436
   PubMed Web of Science ®Google Scholar
• DeanJLMcClendonAKKnudsenESModification of the DNA damage response by therapeutic CDK4/6 inhibitionJ Biol Chem201228734290752908722733811
   PubMed Web of Science ®Google Scholar
• JohnsonNShapiroGICyclin-dependent kinase 4/6 inhibition in cancer therapyCell Cycle20121121391323032266
   PubMed Web of Science ®Google Scholar
• SchwartzGKLoRussoPMDicksonMAPhase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)Br J Cancer2011104121862186821610706
   PubMed Web of Science ®Google Scholar
• FlahertyKTLorussoPMDemicheleAPhase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerClin Cancer Res201218256857622090362
   PubMed Web of Science ®Google Scholar
• DeMicheleASanders ClarkAHeitjanDA Phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancerPaper presented at: 2013 ASCO Annual Meeting2013
   Google Scholar
• SlamonDJHurvitzSAApplebaumSPhase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancerPaper presented at: 2010 ASCO Annual Meeting2010Chicago, IL
   Google Scholar
• FinnRSCrownJPLangIResults of a randomized Phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)Paper presented at: IMPAKT Breast Cancer Conference 2012May 5; 2012Belgium
   Google Scholar
• FinnRSCrownJPLangIResults of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)Paper presented at: Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer SymposiumDecember 4–8, 2012San Antonio, TX
   Google Scholar
• FinnRSCrownJPLangIFinal results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1; TRIO-18)Paper presented at: AACR Annual Meeting 2014April 6, 2014San Diego, CA
   Google Scholar
• FinnRSDierasVGelmonKAA randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(−) breast cancer who have not received any prior systemic anticancer treatment for advanced diseaseASCO Meeting Abstracts201331Suppl 15TPS652
   Google Scholar